Egetis Therapeutics AB (PDPHF) Stock Statistics & Valuation Metrics

Egetis Therapeutics AB has a market cap or net worth of $322.42M. The enterprise value is $2.11K.

Egetis Therapeutics AB has 464,947,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Egetis Therapeutics AB’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -79.16%.

The current PE Ratio of Egetis Therapeutics AB is ―. Egetis Therapeutics AB’s PEG ratio is 0.34.

In the last 12 months, Egetis Therapeutics AB had revenue of 62.40M and earned -342.50M in profits. Earnings per share was -0.93.

In the last 12 months, operating cash flow was -265.30M and capital expenditures -1.20M, giving a free cash flow of -266.50M billion.

Egetis Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Egetis Therapeutics AB upcoming earnings date is Aug 21, 2026, TBA (Confirmed).

Egetis Therapeutics AB as a current ratio of 1.05, with Debt / Equity ratio of 30.25%

In the past 12 months, Egetis Therapeutics AB has paid 400.00K in taxes.

Egetis Therapeutics AB EV to EBITDA ratio is -5.36, with an EV/FCF ratio of -6.85.

Egetis Therapeutics AB has $142.50M in cash and marketable securities with $75.20M in debt, giving a net cash position of $67.30M billion.

Gross margin is 14.24%, with operating margin of -555.93%, and net profit margin of -548.88%.

The average price target for Egetis Therapeutics AB is $2.37, which is 11.43% higher than the current price. The consensus rating is Moderate Buy